The global sclerotherapy market size was valued at USD 1,011.7 million in 2022 and is projected to reach a value of USD 1,768.1 million by 2031, registering a CAGR of 6.4% during the forecast period (2023-2031). The growing elderly population influences sclerotherapy market share, rising incidence of varicose veins, technical improvements in venous disorders, and increased desire for minimally invasive procedures. Factors such as prevalence of venous disorder and technological advancement, significantly drives the sclerotherapy market demand by 2031.
Sclerotherapy is a medical treatment for varicose and spider veins. It entails injecting a solution (sclerosant) directly into the afflicted veins, causing them to collapse and fade over time. This minimally invasive treatment is frequently used to enhance the esthetic look of veins and relieve symptoms of venous insufficiency.
The rising prevalence of thrombotic disorders that cause stroke or mesenteric ischemia, as well as the rising incidence of varicose veins, are projected to drive Sclerotherapy industry growth over the forecast period. Furthermore, recent advancements in cardiology, such as revascularization and cardiogenic shock, will pave the way for market expansion. However, complications in dermatology are expected to slow market expansion.
The high incidence of venous diseases, such as varicose and spider veins, greatly adds to sclerotherapy demand. There is always a need for effective, least-intrusive therapies because these illnesses are so frequent. Varicose veins are a prevalent venous condition that affects a large percentage of the world's population. Individuals with this issue frequently seek medical procedures such as sclerotherapy for both medical and cosmetic reasons. Venous stasis ulcers, for example, harm roughly 500,000 persons.
The incidence of varicose veins varies widely, according to 2019 research published in the International Journal of Preventive Medicine, with estimates ranging from 10% to 60% in adults. According to the study, varicose veins are a prevalent vascular condition that affects both men and women. The likelihood of getting varicose veins rises with age. According to a comprehensive review published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders in 2016, the prevalence of varicose veins increases with age, with a considerable increase noted in people over 40. The frequency of venous diseases directly influences the sclerotherapy market trend.
Alternative treatment methods, such as endovenous laser therapy (EVLT) or radiofrequency ablation (RFA), may represent a barrier to the sclerotherapy market's expansion. Alternative procedures may be chosen by patients and healthcare practitioners depending on unique factors. According to a 2020 research published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders, the adoption of alternative therapies for varicose veins, such as endovenous thermal ablation technologies like EVLT, is on the rise. According to the study, factors such as the size and location of the veins, patient preferences, and the surgeon's experience impact the decision between sclerotherapy and alternative techniques.
Similarly, technical improvements in the field of venous interventions have been continuous. Another alternative treatment that employs heat to seal up troublesome veins is radiofrequency ablation (RFA). This approach, like EVLT, demonstrates the ongoing progress of less invasive treatments, providing patients with options other than standard sclerotherapy.
Ongoing research and development in sclerosant agents present a commercial potential. Innovative formulations and delivery systems can improve sclerotherapy's effectiveness and safety, broadening its applicability to a larger spectrum of venous diseases. A foam combination of a liquid sclerosant and air or another gas is created to employ foam sclerotherapy. This foam has been found to efficiently displace blood from the treated vein, allowing for more contact between the sclerosant and the vein wall. Foam sclerotherapy effectively treats bigger varicose veins in studies such as one published in the "Journal of Vascular Surgery: Venous and Lymphatic Disorders" in 2019.
Microfoam sclerosants, which have smaller bubble diameters in the foam, are also a technical improvement. They are intended to increase sclerosant dispersion inside the vein, potentially enhancing treatment success rates. According to research, including a study published in the "Journal of the American Academy of Dermatology" in 2018, microfoam sclerosants can cure spider veins.
| Study Period | 2019-2031 | CAGR | 6.4% |
| Historical Period | 2019-2021 | Forecast Period | 2023-2031 |
| Base Year | 2022 | Base Year Market Size | USD 1,011.7 Million |
| Forecast Year | 2031 | Forecast Year Market Size | USD 1768.1 Million |
| Largest Market | North America | Fastest Growing Market | Asia Pacific |
The global sclerotherapy market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America.
North America is the most significant global Sclerotherapy market shareholder and is estimated to grow at a CAGR of 6.5% over the forecast period. The observed phenomenon can be linked to the upward trend in research and development spending and the notable presence of multinational corporations. Based on data provided by the Society of Vascular Surgery, it has been observed that a significant proportion of women, around 33.0%, and males, approximately 17.0%, sought medical consultation to treat telangiectasias and varicose veins in developed nations. These conditions have been shown to impact up to 35.0% of individuals residing in the United States and Europe. The prevalence of varicose veins in the United States exceeds 40.0 million individuals, with about 50.0% of affected individuals reporting a familial predisposition.
Additionally, it is noteworthy that in 2022, about 17.3 percent of the populace residing in the United States was 65 years or older. This percentage reflects a notable rise compared to preceding years and is projected to escalate to 22 percent by 2050. The sclerotherapy market share in the area has been driven by factors such as the rising technical breakthroughs in the field of venous disorders, the presence of a large senior population affected by varicose veins, and the growing popularity of less invasive treatment options.
Asia-Pacific is anticipated to exhibit a CAGR of 6.8% over the forecast period. This can be attributed to the increasing number of elderly individuals and sedentary lifestyles in growing nations such as India and China. According to a report by NewsGram, 7.0% of India's young population has varicose veins due to a sedentary lifestyle. In nations such as China, a significant population of 100.0 million individuals has the condition of varicosities, with 40.0 percent of them being affected by varicose veins in the lower extremities. Based on data from the United Nations Population Fund, it is projected that the population of individuals aged 60 years and above in the specified region will see a significant increase, surpassing a total of 1.3 billion by the year 2050. By the mid-21st century, the proportion of individuals aged 60 or beyond is projected to reach 25%, in contrast to the current figure of 10%.
In addition, in East and North-East Asia, the proportion of old individuals is projected to increase significantly, with approximately one in three individuals over 60. Moreover, it is anticipated that most of this senior population will consist of women. The following variables will influence the market within the specified region over the projected timeframe.
Europe is a significant market player. Sclerotherapy is a commonly employed therapeutic intervention for managing varicose and spider veins. It has garnered significant recognition in Europe due to its minimally invasive nature and efficacy in addressing venous problems. The European market is subject to the effect of several elements, encompassing the incidence of venous disorders, technological improvements, the regulatory framework, and the preferences of patients. As an example, it has been shown that around 40% of the adult population residing in Europe experiences the presence of chronic venous illness.
Furthermore, it was anticipated that in the year 2022, the population of Europe amounted to around 743.5 million individuals. Notably, the age group with the highest frequency was 36 years, including over 10.6 million individuals. In comparison, the number of individuals aged 100 or older in the current year amounted to 164,449.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global sclerotherapy market is segmented based on type, agent, and region.
The market is further segmented by agent into Detergents, Chemical Irritants, and Osmotic Agents.
Detergents hold the major market share. Detergents are sclerosant agents that are utilized in sclerotherapy. They force the endothelial cells lining the blood arteries to clump together and seal off. This is referred to as endothelial disruption. The detergents segment held the greatest market share of 45% in 2022 and is predicted to grow fastest during the forecast period. Detergents and sclerosing agents in doses ranging from 0.05% to 0.5% are used to treat spider telangiectasias. These detergents function by producing endothelium damage or desquamation of endothelial cells in plaques via interfering with cell surface lipids, a phenomenon known as protein theft denaturation. Sodium Morrhuate (SM), Ethanolamine Oleate (EO), Sodium Tetradecyl Sulphate (Sotradecol), Polidocanol, and Scleremo are the most frequent detergents.
Chemical irritants are sclerosant substances that cause irritation and inflammation in the walls of blood vessels. This inflammation causes the treated vein to close. Chemical irritant sclerosants now utilized in the United States are generally confined to 72% glycerin.
The market can be bifurcated by type into Ultrasound, Liquid, and Foam.
Liquid type is a significant contributor to the market. The liquid sclerotherapy segment has the largest market share of 40% in 2022 and is growing at a considerable CAGR throughout the projected period. The liquid sclerosant substance is injected directly into the targeted veins during liquid sclerotherapy. The liquid sclerosant produces vein irritation and closure, resulting in the desired therapeutic effect. Small varicose veins and telangiectasias are treated with liquid sclerotherapy. Despite these advancements, liquid sclerotherapy remains the primary treatment choice for tiny varicose veins and telangiectasia, also known as spider veins.
Over the projection period, the foam sclerotherapy segment has the greatest CAGR. Foam sclerotherapy is based on the air-block approach, which involves injecting a tiny bubble of air into the target vessel and then injecting the sclerosant into the bubble's center.
